Moderna, Inc. declined 1.55% in intraday trading. The company highlighted the success of Operation Warp Speed and its role in developing a COVID-19 vaccine, which helped end the pandemic. Additionally, Moderna presented data on mRNA-3927 for the treatment of Propionic Acidemia and mRNA-3705 for Methylmalonic Acidemia at ICIEM 2025, showcasing its ongoing research and development efforts in rare metabolic disorders.
Comments
No comments yet